Articles From: BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment to BioMarin Announces Proposed Offering of $300 Million of Senior Subordinated Convertible Notes Due 2018 and $300 Million Senior Subordinated Convertible Notes Due 2020


2014/1/21
- CE Mark registration trial for BL-5010P expected to begin H1 2014; results expected H2 2014 - JERUSALEM , Jan.
Sign-up for BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment investment picks
2014/1/23
- BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia - - BL-8040 expected to commence Phase 1 trial in stem cell mobilization in Q2 2014; top-line results expected in H2 2014 - JERUSALEM , Jan.
Sign-up for BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment investment picks
2013/11/4
- Study expected to begin by end of 2013 - - Results expected in mid-2014 - JERUSALEM , Nov.
Sign-up for BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease investment picks
2013/11/19
- Results published in Clinical Cancer Research - - Additional clinical trial in stem cell mobilization expected to commence in H1 2014 - JERUSALEM , Nov.
Sign-up for BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma investment picks
2013/8/6
JERUSALEM , Aug.
Sign-up for BioLineRx Reports Second Quarter 2013 Results investment picks
JERUSALEM , Nov.
Sign-up for BioLineRx Reports Third Quarter 2013 Financial Results investment picks
2014/3/17
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2013.
Sign-up for BioLineRx Reports Year End 2013 Financial Results investment picks
JERUSALEM , Nov.
Sign-up for BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013 investment picks
2013/9/3
JERUSALEM , Sept.
Sign-up for BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York investment picks
JERUSALEM , Aug.
Sign-up for BioLineRx to Present at 15th International Celiac Disease Symposium investment picks
JERUSALEM , Aug.
Sign-up for BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston investment picks
2014/1/7
JERUSALEM , Jan.
Sign-up for BioLineRx to Present at Biotech Showcase Conference in San Francisco investment picks
2014/2/3
JERUSALEM , Feb.
Sign-up for BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10 investment picks
2014/3/5
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26 th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.
Sign-up for BioLineRx to Present at the Annual ROTH Growth Stock Conference in California investment picks
2014/3/11
BioLineRx Ltd.
Sign-up for BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014 investment picks
BioLineRx Ltd.
Sign-up for BioLineRx to Report Second Quarter 2013 Results on August 6, 2013 investment picks
2013/11/6
- Management to hold conference call at 10:00 a.m. EST - JERUSALEM , Nov.
Sign-up for BioLineRx to Report Third Quarter 2013 Results on November 13, 2013 investment picks
JERUSALEM , Sept.
Sign-up for BioLineRx's BL-8040 Receives Orphan Drug Designation for Treatment of AML investment picks
2014/1/13
Biologics, Inc., an integrated oncology services company, is pleased to announce that it has been selected by ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) to be the sole specialty pharmacy provider of Iclusig ® (ponatinib) and manager of its Patient Access and Support Services (ARIAD PASS TM ) program.
Sign-up for Biologics Selected by ARIAD to Be the Exclusive Specialty Pharmacy Provider for Iclusig (ponatinib) investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0893650001&sourceType=1 http://media3.marketwire.com/logos/20130121-logo_BL.jpg TORONTO, ONTARIO --
Sign-up for Biologix Hair Inc. Announces 1 for 2 Reverse Split investment picks
2013/8/2
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0890292001&sourceType=1 http://media3.marketwire.com/logos/20130121-logo_BL.jpg TORONTO, ONTARIO --
Sign-up for Biologix Hair Inc. Voluntarily Suspends SEC Reporting Obligations investment picks
2014/1/21
SAN RAFAEL, Calif., Jan.
Sign-up for BioMarin Announces Agreement With Repligen for Pre-clinical Compounds investment picks
2013/10/10
SAN RAFAEL, Calif., Oct.
Sign-up for BioMarin Announces Exercise by Underwriters of Full Over-Allotment Option investment picks
2014/2/14
SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome investment picks
2014/2/26
Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM™ Underway; Positive CHMP Opinion Received February 20 Financial Highlights ($ in millions, except per share data, unaudited)   Three Months Ended December 31, Twelve Months Ended December 31,   2013 2012 % Change 2013 2012 % Change               Total BioMarin Revenue  $ 146.9  $ 131.9 11.4%  $ 548.5  $ 500.7 9.5% Total BioMarin Revenue              (excluding Aldurazyme Net Product Transfer Revenue) - non-GAAP  148.5  131.2 13.2%  553.4  498.9 10.9% Naglazyme Net Product Revenue  68.7  63.0 9.0%  271.2  257.0
Sign-up for BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results investment picks
SAN RAFAEL, Calif., Nov.
Sign-up for BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome investment picks
2014/3/5
SAN RAFAEL, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing on March 4, 2014 of an underwritten public offering of 1,500,000 shares of its common stock.
Sign-up for BioMarin Announces Pricing of Public Offering of Common Stock investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment to BioMarin Announces Proposed Offering of $300 Million of Senior Subordinated Convertible Notes Due 2018 and $300 Million Senior Subordinated Convertible Notes Due 2020
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity